The effective constituent puerarin, from Pueraria lobata, inhibits the proliferation and inflammation of vascular smooth muscle in atherosclerosis through the miR-29b-3p/IGF1 pathway

References

• Bao L, Zhang Y, Wei G, Wang Y, Ma R, Cheng R, Ren X, Agula B. 2015. The anti-atherosclerotic effects of puerarin on induced-atherosclerosis in rabbits. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 159(1):053–059.
   PubMed Web of Science ®Google Scholar
• Boezio B, Audouze K, Ducrot P, Taboureau O. 2017. Network-based approaches in pharmacology. Mol Inf. 36(10):1700048.
   Web of Science ®Google Scholar
• Bruen R, Fitzsimons S, Belton O. 2019. miR-155 in the resolution of atherosclerosis. Front Pharmacol. 10:463.
   PubMed Web of Science ®Google Scholar
• Chen X, Guo X, Ge Q, Zhao Y, Mu H, Zhang J. 2019. ER stress activates the NLRP3 inflammasome: a novel mechanism of atherosclerosis. Oxid Med Cell Longev. 2019:3462530.
   PubMed Web of Science ®Google Scholar
• Chen X, Yu J, Shi J. 2018. Management of diabetes mellitus with puerarin, a natural isoflavone from Pueraria lobata. Am J Chin Med. 46(8):1771–1789.
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Melnichenko AA, Grechko AV, Myasoedova VA, Orekhov AN. 2018. Potential of anti-inflammatory agents for treatment of atherosclerosis. Exp Mol Pathol. 104(2):114–124.
   PubMed Web of Science ®Google Scholar
• Cui T, Tang S, Liu C, Li Z, Zhu Q, You J, Si X, Zhang F, He P, Liu Z, et al. 2018. Three new isoflavones from the Pueraria montana var. lobata (Willd.) and their bioactivities. Nat Prod Res. 32(23):2817–2824.
   PubMed Web of Science ®Google Scholar
• Feng M, Xu D, Wang L. 2018. MiR-26a inhibits atherosclerosis progression by targeting TRPC3. Cell Biosci. 8:4.
   PubMed Web of Science ®Google Scholar
• Gao C, Huang Q, Liu C, Kwong CHT, Yue L, Wan JB, Lee SMY, Wang R. 2020. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat Commun. 11(1):2622.
   PubMed Web of Science ®Google Scholar
• Genkel VV, Kuznetcova AS, Shaposhnik II. 2020. Biomechanical forces and atherosclerosis: from mechanism to diagnosis and treatment. Curr Cardiol Rev. 16(3):187–197.
   PubMed Web of Science ®Google Scholar
• Giral H, Kratzer A, Landmesser U. 2016. MicroRNAs in lipid metabolism and atherosclerosis. Best Pract Res Clin Endocrinol Metab. 30(5):665–676.
   PubMed Web of Science ®Google Scholar
• Hopkins AL. 2008. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 4(11):682–690.
   PubMed Web of Science ®Google Scholar
• Hu Y, Li H, Li R, Wu Z, Yang W, Qu W. 2020. Puerarin protects vascular smooth muscle cells from oxidized low-density lipoprotein-induced reductions in viability via inhibition of the p38 MAPK and JNK signaling pathways. Exp Ther Med. 20(6):270.
   PubMed Web of Science ®Google Scholar
• Ji L, Du Q, Li Y, Hu W. 2016. Puerarin inhibits the inflammatory response in atherosclerosis via modulation of the NF-kappaB pathway in a rabbit model. Pharmacol Rep. 68(5):1054–1059.
   PubMed Web of Science ®Google Scholar
• Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. 2017. Oxidative stress in atherosclerosis. Curr Atheroscler Rep. 19(11):42.
   PubMed Web of Science ®Google Scholar
• Kobiyama K, Ley K. 2018. Atherosclerosis. Circ Res. 123(10):1118–1120.
   PubMed Web of Science ®Google Scholar
• Li S, Zhang B. 2013. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 11(2):110–120.
   PubMed Web of Science ®Google Scholar
• Li Y, Tian L, Sun D, Yin D. 2019. Curcumin ameliorates atherosclerosis through upregulation of miR-126. J Cell Physiol. 234(11):21049–21059.
   PubMed Web of Science ®Google Scholar
• Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgözoğlu L, Lewis EF. 2019. Atherosclerosis. Nat Rev Dis Primers. 5(1):56.
   PubMed Web of Science ®Google Scholar
• Luo TT, Lu Y, Yan SK, Xiao X, Rong XL, Guo J. 2020. Network pharmacology in research of Chinese medicine formula: methodology, application and prospective. Chin J Integr Med. 26(1):72–80.
   PubMed Web of Science ®Google Scholar
• Marchio P, Guerra-Ojeda S, Vila JM, Aldasoro M, Victor VM, Mauricio MD. 2019. Targeting early atherosclerosis: a focus on oxidative stress and inflammation. Oxid Med Cell Longev. 2019:8563845.
   PubMed Web of Science ®Google Scholar
• Qiao XR, Wang L, Liu M, Tian Y, Chen T. 2020. MiR-210-3p attenuates lipid accumulation and inflammation in atherosclerosis by repressing IGF2. Biosci Biotechnol Biochem. 84(2):321–329.
   PubMed Web of Science ®Google Scholar
• Rahman MS, Woollard K. 2017. Atherosclerosis. Adv Exp Med Biol. 1003:121–144.
   PubMed Web of Science ®Google Scholar
• Tam WY, Chook P, Qiao M, Chan LT, Chan TY, Poon YK, Fung KP, Leung PC, Woo KS. 2009. The efficacy and tolerability of adjunctive alternative herbal medicine (Salvia miltiorrhiza and Pueraria lobata) on vascular function and structure in coronary patients. J Altern Complement Med. 15(4):415–421.
   PubMed Web of Science ®Google Scholar
• Vaidyanathan K, Gopalakrishnan S. 2017. Nanomedicine in the diagnosis and treatment of atherosclerosis-A systematic review. Cardiovasc Hematol Disord Drug Targets. 17(2):119–131.
   PubMedGoogle Scholar
• Wang C, Niimi M, Watanabe T, Wang Y, Liang J, Fan J. 2018. Treatment of atherosclerosis by traditional Chinese medicine: questions and quandaries. Atherosclerosis. 277:136–144.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang S, Wang S, Gao P, Dai L. 2020. A comprehensive review on Pueraria: insights on its chemistry and medicinal value. Biomed Pharmacother. 131:110734.
   PubMed Web of Science ®Google Scholar
• Wang X, Li C, Zhou Z, Zhang Y. 2019a. Identification of three (iso)flavonoid glucosyltransferases from Pueraria lobata. Front Plant Sci. 10(28):28.
   PubMedGoogle Scholar
• Wang Z, Zhang J, Zhang S, Yan S, Wang Z, Wang C, Zhang X. 2019b. MiR30e and miR92a are related to atherosclerosis by targeting ABCA1. Mol Med Rep. 19:3298–3304.
   PubMed Web of Science ®Google Scholar
• Wolf D, Ley K. 2019. Immunity and inflammation in atherosclerosis. Circ Res. 124(2):315–327.
   PubMed Web of Science ®Google Scholar
• Xu S, Pelisek J, Jin ZG. 2018. Atherosclerosis is an epigenetic disease. Trends Endocrinol Metab. 29(11):739–742.
   PubMed Web of Science ®Google Scholar
• Zarate A, Manuel-Apolinar L, Basurto L, De la Chesnaye E, Saldivar I. 2016. Cholesterol and atherosclerosis. Historical considerations and treatment. Arch Cardiol Mex. 86(2):163–169.
   PubMedGoogle Scholar
• Zhang S, Wang J, Zhao H, Luo Y. 2018. Effects of three flavonoids from an ancient traditional Chinese medicine radix puerariae on geriatric diseases. Brain Circ. 4(4):174–184.
   PubMedGoogle Scholar
• Zhou YX, Zhang H, Peng C. 2014. Puerarin: a review of pharmacological effects. Phytother Res. 28(7):961–975.
   PubMed Web of Science ®Google Scholar
• Zhu J, Liu B, Wang Z, Wang D, Ni H, Zhang L, Wang Y. 2019. Exosomes from nicotine-stimulated macrophages accelerate atherosclerosis through miR-21-3p/PTEN-mediated VSMC migration and proliferation. Theranostics. 9(23):6901–6919.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, Han X, Tang D, Chen R. 2018. Research progress on the relationship between atherosclerosis and inflammation. Biomolecules. 8(3):80.
   PubMed Web of Science ®Google Scholar